NSW Sets THC Driving Limit for Medical Cannabis Patients

NSW Abandons Zero-Tolerance THC Policy

New South Wales becomes the first Australian state to permit medical cannabis patients to drive with detectable THC in their system, contingent on staying below a statutory blood-concentration threshold. The reform reverses the Road Transport Act 2013 (NSW) s 111(1)(b), which criminalized driving with any detectable presence of THC, regardless of impairment. Patients holding valid Therapeutic Goods Administration approvals or Special Access Scheme authorizations will face prosecution only if their THC blood concentration exceeds the prescribed limit at the time of testing.

The government hasn't published the numeric threshold yet. Transport for NSW indicated the limit will be set following consultation with the National Drug Driving Working Group and toxicology experts from the National Measurement Institute. The threshold will apply to delta-9-tetrahydrocannabinol measured in whole blood, not oral fluid. That means evidentiary blood draws, not roadside saliva screens, for prosecution.

Legal Framework Mirrors Alcohol Per Se Limits

The THC limit will function as a per se offense under NSW traffic law, analogous to the 0.05% blood alcohol concentration standard for non-commercial drivers. Drivers exceeding the THC threshold face automatic penalties. The prosecution doesn't need to prove observable impairment. The reform doesn't create an affirmative defense for patients; it establishes a safe harbor below the limit and strict liability above it.

The amendment will be enacted through regulation under the Road Transport Act 2013 (NSW), not primary legislation. This allows the Minister for Roads to adjust the threshold by statutory instrument without returning to Parliament, a structure identical to the framework governing prescribed drug schedules in s 111(1). The regulation is expected to take effect in the second half of 2026, pending finalization of the blood-concentration standard.

Compliance Burden Shifts to Patients

Medical cannabis patients will bear the responsibility of ensuring their THC levels remain below the legal threshold before operating a vehicle. No official guidance has been issued on washout periods, dosing schedules, or testing protocols to verify compliance. The NSW Ministry of Health hasn't announced plans for patient education materials or subsidized testing access. Prescribers and patients must develop compliance strategies independently.

Australia lacks a commercially available, patient-accessible THC blood test. Pathology labs can perform quantitative THC assays on venous blood samples, but these require a doctor's order and cost between AUD 150 and AUD 300 per test. No Medicare rebate. Patients using daily or high-dose regimens may need serial testing to establish individual clearance curves, a cost the government hasn't addressed.

Roadside Testing Protocols Remain Unclear

Police will continue to use oral fluid screening devices at roadside drug testing checkpoints, but these devices return only qualitative positive/negative results, not quantitative THC concentrations. A positive saliva screen triggers an evidentiary blood draw at a police station or hospital, with prosecution contingent on the blood result exceeding the statutory limit. Patients testing positive on oral fluid but below the blood threshold will still be detained, transported, and subjected to venipuncture before clearance.

Transport for NSW hasn't clarified whether patients can present their TGA approval at roadside to avoid detention pending blood confirmation. The standard operating procedure for roadside drug testing under the Law Enforcement (Powers and Responsibilities) Act 2002 (NSW) doesn't currently include an exemption or expedited-release pathway for authorized patients. For full background on this issue, see the CannIntel topic hub on Australia Medical Cannabis Driving Laws.

The reform grants medical cannabis patients conditional mobility rights but imposes a compliance and cost structure that may exceed the capacity of low-income or regional patients to navigate.

Interstate Implications and Federal Coordination

No other Australian state has announced plans to adopt a THC driving limit, leaving medical cannabis patients subject to zero-tolerance enforcement in Victoria, Queensland, South Australia, Western Australia, Tasmania, and the Northern Territory. A patient legally driving in NSW with sub-threshold THC could face criminal prosecution upon crossing the state border into Victoria or Queensland, where any detectable THC remains a strict-liability offense under respective road safety acts.

The National Transport Commission, which coordinates model road laws across jurisdictions, hasn't endorsed the NSW approach. The Australian Medical Association and the Royal Australasian College of Physicians haven't issued formal positions on impairment-based THC limits. No peer-reviewed Australian research has validated a blood-THC threshold correlating to driving impairment in chronic medicinal users. Once published, the NSW threshold will lack empirical support from local pharmacokinetic studies.

What Comes Next

Transport for NSW will release the numeric THC limit and procedural regulations in the coming months. Stakeholders will be watching three variables: the threshold level, the blood-testing protocol, and whether the government funds patient compliance tools. Without subsidized testing or clear washout guidance, the reform may function as a de facto prohibition for patients unable to afford serial monitoring.